ACHV · XBRL financial data

Achieve Life Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACHV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	3,581	2,114*	2,799	5,113	7,609	7,296*	7,097	6,707	5,320	—	—	—
General and administrative	2,991	2,272*	3,183	3,318	4,857	4,894*	5,797	5,856	9,372	—	—	—
Interest income	262	208*	368	833	673	482*	322	192	554	427*	297	1,476
Interest expense	781	787*	813	804	366	197*	185	191	192	251*	274	277
Other income (expense)	(17)	17*	(15)	(2)	(8)	(5)*	21	(59)	(5)	7*	(13)	(5)
Net income (loss)	(7,108)	(5,476)*	(6,494)	(8,461)	(12,512)	(12,360)*	(12,827)	(12,718)	(14,441)	(14,662)*	(10,168)	(74,769)
Earnings per share, basic USD per share	(0.34)	(0.26)*	(0.26)	(0.25)	(0.36)	(0.36)*	(0.37)	(0.37)	(0.28)	(0.27)*	(0.19)	(0.80)
Earnings per share, diluted USD per share	(0.34)	(0.26)*	(0.26)	(0.25)	(0.36)	(0.36)*	(0.37)	(0.37)	(0.28)	(0.27)*	(0.19)	(0.80)
Weighted average shares, basic thousands of shares	21,127	21,166*	25,048	34,319	34,355	34,511*	34,685	34,685	51,018	53,700*	53,382	93,511
Weighted average shares, diluted thousands of shares	21,127	21,166*	25,048	34,319	34,355	34,511*	34,685	34,685	51,018	53,700*	53,382	93,511

Balance sheet

CSV

Fiscal quarters (ACHV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	19,919	15,546	66,398	14,756	9,544	12,753	13,016	51,874	31,930	20,929	28,078	47,958
Short-term investments	—	—	—	46,557	33,367	—	—	—	—	—	—	—
Marketable securities	—	—	—	—	—	21,607	10,229	3,523	16,184	15,475	1,191	139,345
Prepaid and other current assets	1,895	1,325	1,311	1,206	2,618	2,107	1,755	1,506	1,941	—	—	—
Total current assets	21,897	16,982	67,709	62,519	45,529	36,467	25,000	56,903	50,055	39,889	31,061	188,294
Property and equipment, net	—	13	—	—	—	8	—	—	—	3	—	—
Right-of-use asset	80	66	51	35	20	119	106	93	79	64	49	34
Goodwill	1,034	1,034	1,034	1,034	1,034	1,034	1,034	1,034	1,034	1,034	1,034	1,034
Total assets	24,337	19,371	70,029	64,791	47,917	38,633	27,358	58,935	52,040	41,790	33,105	190,439
Accounts payable	638	618	373	550	1,011	1,950	1,656	1,218	1,943	—	—	—
Accrued liabilities	—	—	—	—	—	—	—	—	—	—	—	200
Total current liabilities	4,082	20,813	20,573	13,702	6,716	6,682	7,130	8,573	9,730	9,082	11,833	197,657
Lease liability, non-current	22	6	—	—	—	66	52	37	21	5	—	—
Total liabilities	20,299	20,819	20,573	22,506	16,539	17,734	17,079	17,267	18,425	20,272	22,427	205,115
Accumulated deficit	(160,275)	(165,751)	(172,245)	(180,706)	(193,218)	(205,578)	(218,405)	(231,123)	(245,564)	(260,226)	(270,394)	(345,163)
Total stockholders' equity	4,038	(1,448)	49,456	42,285	31,378	20,899	10,279	41,668	33,615	21,518	10,678	(14,676)
Total liabilities and equity	24,337	19,371	70,029	64,791	47,917	38,633	27,358	58,935	52,040	41,790	33,105	190,439
Common shares outstanding (cover page) thousands of shares	21,166	34,252	34,341	34,341	34,390	34,685	34,685	51,105	53,234	53,240	102,659	102,902

Cash flows

CSV

Fiscal quarters (ACHV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(7,108)	(5,476)*	(6,494)	(8,461)	(12,512)	(12,360)*	(12,827)	(12,718)	(14,441)	(14,662)*	(10,168)	(74,769)
Stock-based compensation	1,174	(10)*	1,288	1,454	1,340	1,243*	2,232	2,888	2,340	1,301*	(685)	6,955
Net cash from operating activities	(5,136)*	(4,364)*	(5,288)	(4,921)*	(10,372)*	(9,189)*	(11,088)	(9,069)*	(11,331)*	(17,977)*	(6,932)	(10,777)*
Purchases of property and equipment	—	6*	—	—	—	—	—	—	—	year only	—	—
Net cash from investing activities	—	(6)*	—	—	13,271*	11,717*	11,353	6,703*	(12,654)*	709*	14,276	(137,804)*
Net cash from financing activities	0*	0*	56,110	(153)*	(8,112)*	682*	—	—	4,042*	6,263*	21	168,458*
Net change in cash	(5,152)*	(4,373)*	50,822	(51,642)*	(5,212)*	3,209*	263	38,858*	(19,944)*	(11,001)*	7,364	19,880*

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.